An American investment bank has warned investors it will soon stop allowing the trading of marijuana companies operating in the US.
The Bank of New York Mellon (BNY Mellon) issued a notice to investors on Monday (September 30), announcing that it will not allow incoming positions or trading of cannabis stocks participating in the US market starting on November 30.
This new mandate only applies to companies with marijuana assets in the US. The bank explained that Canadian companies without any American “operations or distribution” don’t violate the federal Controlled Substances Act.
The bank said moving forward it will consider reviews on positions that “were subject of an order, transaction or incoming transfer to ensure compliance due to federal laws and regulations.”
BNY Mellon indicated that the ban on trading for these stocks is related to the federal illegality of the drug in the US. Cannabis is still a Schedule I drug in the eyes of the federal government, despite the legalization programs seen at the state level.
So far, 11 states and the District of Columbia have legalized marijuana, both for medical and recreational use. Additionally, 22 other states have legalized medical cannabis products.
“BNY Mellon continues to monitor trends in CRB (cannabis-related business) transactions and may impose additional restrictions or require additional information in the future,” the bank said in its note.
The bank asked investors to hold off on trading or transferring these now disallowed securities. BNY Mellon stated in its warning:
During this time period, up until November 30, the effective date, we encourage you to not trade or transfer in any non-permitted CRB securities and BNY Mellon’s Pershing reserves the right to reject any non-permitted CRB trades or deposits. After November 30, BNY Mellon’s Pershing will no longer accept any non-permitted CRB trades or deposits.
In September, the US cannabis industry received a vote of confidence when the House of Representatives approved the Secure and Fair Enforcement Banking Act of 2019, otherwise known as the SAFE Banking Act.
This bill seeks to create protections for banks and other financial institutions willing to offer banking services to cannabis and hemp companies in the US.
The SAFE Banking Act is now en route to the Senate, were it will most likely face an uphill climb to be approved, according to experts.
“The industry is hanging onto the hope that this would make it a lot easier for a lot of these bigger plays to grow a lot quicker, capture market share and bring over the black market to legal channels,” Nawan Butt, associate portfolio manager Purpose Investments, previously told the Investing News Network.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).